Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.

Journal of medical virology - 1 Nov 2021

Bottari Fabio, Iacobone Anna Daniela, Radice Davide, Preti Eleonora Petra, Preti Mario, Franchi Dorella, Piana Andrea Fausto, Sandri Maria Teresa, Passerini Rita

Abstract excerpt

Human papillomavirus (HPV) tests differ for technology, targets, and information on the genotype and viral load. In this study, we evaluated the performance of the Seegene Anyplex II HPV HR (Anyplex) assay in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical treatment. One hundred and sixty-seven women referred to the European Institute of Oncology,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cervix Uteri
Share to Early Detection of Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Reagent Kits, Diagnostic

Share to Uterine Cervical Dysplasia

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 33565607
DOI: 10.1002/jmv.26862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.PMID 33565607Read ↗

Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.Semantic proximity Read ↗

Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2.Semantic proximity Read ↗

Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.Semantic proximity Read ↗

Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.Semantic proximity Read ↗

Evaluation of Seegene Anyplex II Performance for Detection of Human Papillomavirus Genotypes in Formalin-Fixed, Paraffin-Embedded Cervical Cancer Specimens.Semantic proximity Read ↗

The Potential Impact of High-Risk Human Papillomavirus-Negative Cervical Intraepithelial Neoplasia 2+ on Primary Human Papillomavirus Screening.Semantic proximity Read ↗

Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping.Semantic proximity Read ↗

Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.Semantic proximity Read ↗

Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.Semantic proximity Read ↗

Human papillomavirus genotyping for predicting disease progression in women with biopsy-negative or cervical intraepithelial neoplasia grade 1 of low-grade intraepithelial lesion cytology.Semantic proximity Read ↗

Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.Semantic proximity Read ↗

Transition from Hybrid Capture 2 to Cobas 4800 in Hpv detection: sensitivity and specificity for Cin2+ in two time periods.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.